The glucagon-like peptide (GLP1) regulates food consumption and appetite, and its analogs, GLP-1 receptor agonists (GLP-1RAs), are used to treat type 2 diabetes, obesity, and metabolic syndrome
Modeling from the Employee Benefit Research Institute shows that broader GLP1 coverage can increase employer health premiums by 6% to nearly 14% a year, even with costsharing in place
The GLP-1 receptor agonists are generally recommended as a second or third-line option as add-on to metformin therapy in patients with T2DM who do not have ASCVD/indicators of high-risk for ASCVD, HF, or CKD and who need to minimize hypoglycemia and/or promote weight loss
Kunmar also raised HSBCs 12-month price target on Lilly shares by roughly 4%, from $675 to $700
doi:10.1111/obr.13929 Disclaimer : The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition
It offers everything Semaglutide does but gives an extra boost in appetite reduction
